Loading...
•
Sep 30, 2024
EyePoint Pharmaceuticals Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported a total net revenue of $10.5 million for the third quarter ended September 30, 2024, compared to $15.2 million for the quarter ended September 30, 2023. The net loss was $29.4 million, or ($0.54) per share, compared to a net loss of $12.6 million, or ($0.33) per share, for the prior year period. Cash and investments totaled $253.8 million at September 30, 2024.
Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile.
Dosed first patient in Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD; second LUCIA pivotal trial first patient dosing expected by end of 2024.
Completed an oversubscribed equity financing of $161.0 million, extending cash runway into 2027.
Total net revenue was $10.5 million compared to $15.2 million for the quarter ended September 30, 2023.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Revenue by Segment
Revenue by Segment
Product sales, net Revenue
CapyFin.comLicense and royalties Revenue
CapyFin.com Forward Guidance
The company expects the cash, cash equivalents and investments on September 30, 2024, along with the net proceeds from the October $161.0 million equity financing will enable it to fund operations into 2027.
Revenue & Expenses
Visualization of income flow from segment revenue to net income